Global orthopedic sales totaled $59 billion in 2023, an increase of 6.5% compared to 2022. Read our regularly updated analysis of the orthopedic market, including sales forecasts for all segments, company revenue and insight into key trends.
Global orthopedic sales totaled $59 billion in 2023, an increase of 6.5% compared to 2022. Read our regularly updated analysis of the orthopedic market, including sales forecasts for all segments, company revenue and insight into key trends.
Stay up to date on the orthopedic market’s 2Q performance in 2024 as we update this post with company sales data and industry developments.
The U.S. remains the world’s largest orthopedic market by revenue, but companies see significant opportunities for international growth.
Proceeds will be used to increase the company’s market penetration and develop further clinical data in support of the EnFix family of allograft products.
Funds will support commercialization of the InSet Total Shoulder and Reverse systems and new product development.
Over the last four years, spine M&A volume declined significantly while digital and orthobiologic assets saw increased activity.
Additional investment and resources will accelerate Biocomposites’ international expansion and innovation in products for use in infection management.
The company grew in the high single digits in 2024 as it made significant progress integrating its Lima acquisition.
Smith+Nephew’s 12-Point Plan is working and driving improved performance for the company. But is it working fast enough?
OSSTEC has developed 3D-printing technology to mimic cartilage articulating surfaces and bone-fixing structures. Its first product can be applied in less-invasive knee implants to stimulate bone growth.
The investments will support continued growth and the launch of four 3D-printed product lines in 2025 and 2026.
Eventum provides the QuadSense device that helps surgeons precisely cut and place the kneecap in total knee replacements.
Proceeds will be used to increase the company’s market penetration and develop further clinical data in support of the EnFix family of allograft products.
Funds will support commercialization of the InSet Total Shoulder and Reverse systems and new product development.
Over the last four years, spine M&A volume declined significantly while digital and orthobiologic assets saw increased activity.
Additional investment and resources will accelerate Biocomposites’ international expansion and innovation in products for use in infection management.
The company grew in the high single digits in 2024 as it made significant progress integrating its Lima acquisition.
The company grew nearly 27% in 2024 as its technology and procedural approach continued to compel surgeon adoption in the spine market.
Login
Register for a free account
As a guest member you get access to more articles and videos every month.